NCEL

NewcelX Ltd.

NewcelX Ltd. (NCEL) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Profitability (D-). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
B+
Factor Score 3.7 / 5.0
Growth
C+
Factor Score 2.7 / 5.0
Profitability
D-
Factor Score 0.8 / 5.0
Momentum
C-
Factor Score 2.1 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 5.2
EV / EBITDA -3.6
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -19.6%
Price Return 12M -28.3%
Catalyst Signal 0.00
Market Cap $15.5M
TTM Revenue N/A
Price / Sales N/A
ROE N/A

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B+ (3.7) C+ (2.7) D- (0.8) C- (2.1) C+ (2.6) C (2.4)
2026-11-06 B+ (3.6) C+ (2.7) D- (0.8) C (2.5) C+ (2.7) C (2.5)
2026-10-30 B+ (3.7) C+ (2.7) D- (0.8) D+ (1.7) C+ (2.7) C (2.3)
2026-10-23 B+ (3.7) C+ (2.7) D- (0.8) D (1.3) C+ (2.6) C (2.2)
2026-10-16 B+ (3.6) C+ (2.7) D- (0.8) C (2.4) C+ (2.6) C (2.4)
Page 1 of 4